InflaRx N.V.
InflaRx N.V. (NASDAQ: IFRX) is trading at $1.82, about ₹175 at today's USD/INR rate, as of 28 Sep 2026, 4:00 PM ET, down 3.70% today. Indian residents can buy InflaRx from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$1.80
Today's high
$1.95
52 week low
$0.80
52 week high
$2.95
IFRX opened at $1.88, closed previously at $1.89, and has traded between $0.80 and $2.95 over the past 52 weeks.
About
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
Key statistics
Avg. volume
1.02M
Market cap
$268.07M
P/E Ratio
-3.28
Price-to-sales ratio
-23341.27
Enterprise value
€90.10M
Free cash flow yield
-10.16%
Debt-to-equity ratio
0.01
Return on equity
-58.00%
ROIC
-24.89%
Beta
2.54
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
€29.33K
Earnings per share
-€0.66
Free cash flow
-€34.03M
Net profit margin
387532.08%
Gross margin
48201.61%
EBITDA
-€45.16M
Revenue growth
-82.31%
Similar securities
This is not an investment recommendation
How to buy InflaRx from India
Indian residents can buy InflaRx shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for InflaRx and place an order
Find InflaRx by name or by its ticker, IFRX, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. InflaRx trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your InflaRx position in USD and INR. InflaRx pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in InflaRx from India
Trading and taxes when buying InflaRx from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneInflaRx does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy InflaRx stock?
Yes. InflaRx (IFRX) has been listed on NASDAQ since 2017, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one InflaRx share cost in rupees?
One InflaRx share is $1.82 — about ₹175 at a USD/INR rate of 96.07 on 28 Sep 2026. Both the InflaRx price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying InflaRx from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of InflaRx?
Yes. One InflaRx share is $1.82, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in InflaRx.
How are gains on InflaRx shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the InflaRx price. Paasa issues a capital-gains statement for your return.
Does InflaRx pay a dividend?
No. InflaRx does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade InflaRx from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is InflaRx a United States company, and does that change how it is taxed?
InflaRx trades on NASDAQ in US dollars, but the company is domiciled in Germany. InflaRx trades as an ordinary share listed directly in the US, not a depositary receipt. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Your India-side capital-gains treatment is the same either way.
Do I have to declare InflaRx shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your InflaRx holding, its cost and its closing value.
How do I sell InflaRx and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.